Drugs / C1-R212
last change Aug 2017 re-read 2 minutes ago

C1-R212

Developed for
hyperlipoproteinemia · hypertensive disorder

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT02955368 Comparator Feb → Jul 2017 hyperlipoproteinemia, hypertensive disorder Alvogen Korea Withdrawn No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as C1-R212 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02955368